Healthcare Jun 28, 2022 09:57 AM (GMT+8) · EqualOcean
On June 27, 2022, Fosun Pharmaceutical announced that it had successively reached cooperation with Amgen on the commercialization licensing of two innovative drugs of Amgen, namely, apmist tablets (trade name "otailar") and etkapide hydrochloride injection (trade name "parsabiv") in China (excluding Hong Kong, Macao and Taiwan). According to the announcement, Fosun Pharma USA, a subsidiary of Fosun Pharmaceutical Holdings, should pay up to US $47million down payment and regulatory milestones to Kai Pharma, a subsidiary of Amgen holdings, for the licensed products according to the agreement, and pay sales milestones according to the agreement.

This text is a result of machine translation.